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Summary
The efficacy of Fusobacterium
necrophorumcrudeleukotoxoidvaccineto
immunizeandprotectsteersagainstexperi-
mentallyinducedliverabscesseswasevalu-
ated. The vaccineconsistedof cell-fre
culturesupernatantof a highleukotoxin-
producingstrainof F. necrophorum, inacti-
vatedwithformalinandhomogenizedwithan
oil emulsionadjuvant.Vaccinewasinjected
subcutaneouslyon days0 and21. Blood
sampleswerecollectedweeklytomonitor
immuneresponse.Threeweeksafterthe
secondvaccination,steerswere injected
intraportallywithF. necrophorumcultureto
induceliverabscesses.Threeweekslater(day
63),steerswereeuthanatizedandnecropsied;
liverswereexamined,andprotectionwas
assessed.Anti-leukotoxinantibodytitersin
thecontrolsteersgenerallydid notdiffer
fromthebaseline(week0)titers.Thetiters
in thevaccinatedgroupsincreased,moreso
afterthesecondinjection,andtheincrease
wasgenerallydosedependent.At necropsy,
all steersin thecontrolgrouphadliver
abscesses.Inthevaccinatedgroups,twoout
of fivesteersin the1.0mlgroupandone
eachin the2.0,5.0,and2.25ml (concen-
trated)groupshadliverabscesses.Thediffer-
encesuggestsa protectiveffectof anti-
leukotoxinantibodiesagainstexperimentally
inducedliverabscesses.
(Key Words: Liver Abscesses,
Fusobacteriumnecrophorum, Leukotoxoid
Vaccine.)
Introduction
Liverabscessesareofeconomiconcern
to thefeedlotindustrybecausetheycause
livercondemnation,reducedfeedefficiency,
and reducedweightgain. Fusobacterium
necrophorum,istheprimarycausativeagent
of liverabscesses.Theincidenceof liver
abscessesaverages18 to 32% in feedlot
cattleand is relatedto feedinghighgrain
diets.Rapidruminalfermentationfgrainin
therumenresultsin ruminalacidosisand
rumenitis,whichareconsideredtobepredis-
posing factors for liver abscesses.
Fusobacteriumnecrophorum, a normal
inhabitantoftherumen,colonizestheruminal
epithelialwall, reachestheliverviatheportal
circulation,andsetsupinfection.Theability
of F. necrophorumtocolonizeruminalepi-
theliumandestablishinfectionintheliveris
attributedmainlytoapotentleukotoxinthat
istoxic toleukocytes,macrophages,ruminal
epithelialcells,andhepatocytes.Therefore,
immunizingtheanimalagainstthetoxinmay
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prevent the onset of liver abscesses. Our The leukotoxin concentration in the
objectivewasto determinetheefficacyof F. original culture supernatant was 27,020
necrophorumleukotoxoidvaccineto immu- units/ml. Intheculturesupernatantconcen-
nizesteersandto provideprotectionagainst trated5.2-fold, theleukotoxinconcentration
experimentally inducedliver abscesses. was54,040units/ml. Apparently, theprocess
Experimental Procedures
Fusobacterium necrophorum, A25, a leukotoxinconcentration inthe4.5ml dose.
highleukotoxinproducingstrain, previously
isolated from a liver abscess was used to Antibody titers in the control steers in-
preparethevaccine, whichconsistedof cell- jectedwithphosphate-bufferedsalinegener-
free supernatant (original or concentrated allydidnotdiffer fromthebaselinethrough-
5.2 fold) inactivatedbyaddingformalinand outthe6-weeksamplingperiod. Thetiters in
homogenizedwithanoil emulsionadjuvant. the vaccinated steers increased (P<.01) fol-
Theleukotoxicityof theoriginal andconcen- lowing the first vaccination and increased
tratedculturesupernatants, beforeandafter muchmoreafter thesecondinjection(Figure
formalininactivation, wasdetermined. 1). A significant treatment x week interac-
Twenty-fiveHolstein steers (meanbody bodytitersappearedto berelatedto thedose
weight860lb), fedadlibitumadietof alfalfa of leukotoxoid, withthe1.0ml doseeliciting
hay, wereassignedrandomly to fivegroups: thelowestantibodytitersandthe5.0ml dose
control; thre doses(1.0, 2.0, and5.0ml) of elicitingthehighest.Thepurposeof usingthe
the culture supernatant; and a dose of the concentrated supernatant was to determine
concentrated supernatant (2.25 ml) equiva- whetherconcentratingtheculturesupernatant
lenttotheleukotoxinconcentrationin4.5ml toreducetheinjectionvolumewouldalter its
of theoriginal culturesupernatant (Table1). immunogenicityor protectiveeffect. Appar-
Eachsteer inthecontrol groupreceived4.5 ently, concentrating the culture supernatant
ml of phosphate buffer saline mixed with reduced its immunogenicity asevidencedby
adjuvant. All injectionsweregivensubcuta- lower antibody titers.
neouslyondays0and21.
Jugular blood sampleswerecollected at grouphadliverabscesseascomparedto two
weekly intervalsafter thefirstvaccinationto out of five steers in the 1.0-ml-vaccinated
monitor the immuneresponse. Serumsam- groupandoneeachinthe2.0, 5.0, and2.25
ples were assayed for anti-leukotoxin anti- ml (concentrated) groups (Table2). Based
body titers. Three weeks after the second onFisher’sexacttest(2-tail), theincidenceof
vaccination, steers were inoculated intra- liver abscessewas lower (P<0.01) in the
portally by an ultrasound-guided, percut- vaccinatedgroups(al four doses) thaninthe
aneous, catheterization procedure with F. control. Steers that developed abscesse
necrophorum to induce liver abscesse (n=10) had lower anti-leukotoxin titers
Steers were euthanatized 21 days after the (P<0.05) duringwk 1to 6thanthosesteers
intraportal challenge and examined for ab- 
scesses and other gros lesions in the liver 
andother organs.
Resultsand Discussion
of concentration reduced the leukotoxin
activity. Therefore, 2.25 ml of theconcen-
trated supernatant was used to equal the
tion(P <.01) occurred. Generally, theanti-
Atnecropsy, al fivesteers inthecontrol
(n=15) that did not develop abscesses in the
liver, regardless of the treatment (Figure 2).
degre  of protection against experimentally
induced liver abscesses. However, further
Our results indicate that F. necrophorum
studies are required to determine the efficacy
culture supernatant was capable’ of eliciting
of the vaccine in feedlot cattle with naturally
developing liver abscesses.
anti-leukotoxin immunity that provided some
Table 1. Treatment Groups and Leukotoxin Concentration in the Culture
Supernatant
Culture Concentrated Phosphate Leukotoxin
Treatment
Control
Supernatant Supernatanta Buffered- Adjuvant Titer per
(ml) (ml) Saline (ml) (ml) Dose
— — 4.5 .5 —
Culture
supernatant, 1.0 ml
0.9 — .l 24,318
Culture
supernatant, 2.0 ml
1.8 — .2 48,636
Culture
supernatant, 5.0 ml
4.5 — .5 121,590
Concentrated
supernatant, 2.25 ml
2.25 2.25 .5 121,590
a Culture supernatant concentrated 5.2-fold
Table 2. Experimental Induction of Liver Abscesses in Control or Vaccinated Steers
Liver Abscesses
Treatment No. of Steers Necropsya Incidence (%)
Control 5 5/5 100
Culture supernatant, 1.0 ml 5 2/5 40
Culture supernatant, 2.0 ml 5 1/5 20
Culture supernatant, 5.0 ml 5 1/5 20
Concentrated supernatant, 2.25 mlb 5 1/5 20
aFisher’s exact test (2-tail), control vs. vaccinated P  < .01.
bCulture supernatant concentrated 5.2-fold.
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Figure 1. Serum Leukotoxin-Neutralizing Antibody Titers in Controls or Steers
Vaccinated with 1.0, 2.0, or 5.0 ml Culture Supernatant and 2.25 ml of the
Concentrated (C) Supernatant.  SEM = 1.6, Treatment Effect P<.0l, Week
Effect P<.0l, and Treatment x Week Interaction P<.05.
Figure 2. Serum Leukotoxin-Neutralizing Antibody Titers in Steers that Developed
(N=10) or Did Not Develop (N=15) Liver Abscesses. SEM=1.4, Abscess
Effect P<.05, Week Effect P<.01).
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